10-Q: Rapport Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Rapport Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting progress in its clinical programs and a recent FDA clinical hold on a trial for diabetic peripheral neuropathic pain.

Summary

• Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for central nervous system disorders.
• The company's lead product candidate, RAP-219, is being developed for focal epilepsy, peripheral neuropathic pain, and bipolar disorder.
• A Phase 2a proof-of-concept trial for RAP-219 in focal epilepsy is underway, with topline results expected in mid-2025.
• The FDA placed a clinical hold on the Phase 2a trial of RAP-219 for diabetic peripheral neuropathic pain, requesting additional protocol information.
• A second MAD clinical trial of RAP-219 is expected to be completed by the end of 2024, with topline results expected in the first quarter of 2025.
• A Phase 1 PET clinical trial for RAP-219 has been initiated, with topline results expected in the first quarter of 2025.
• The company is deferring further investment in RAP-199 to focus on RAP-219.
• Rapport Therapeutics reported a net loss of $17.5 million for the three months ended September 30, 2024, and $58.3 million for the nine months ended September 30, 2024.
• As of September 30, 2024, the company had cash, cash equivalents, and short-term investments of $320.7 million.
• The company expects its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through the end of 2026.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a strong cash position and is progressing with its lead program, the FDA clinical hold and significant losses temper the positive aspects. The sentiment is neutral to slightly negative.

Positives

• The company has sufficient cash to fund operations through the end of 2026.
• The Phase 2a trial for focal epilepsy is underway and progressing.
• The company has initiated a Phase 1 PET clinical trial for RAP-219.
• The company is focusing resources on its lead product candidate, RAP-219.

Negatives

• The FDA placed a clinical hold on the Phase 2a trial of RAP-219 for diabetic peripheral neuropathic pain.
• The company has incurred significant operating losses since its inception.
• The company is dependent on third parties for manufacturing and clinical trials.
• The company has a limited operating history.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate its current business and predict its future success and viability.
• The company has incurred significant financial losses since its inception and anticipates that it will continue to incur significant financial losses for the foreseeable future.
• The company will require additional funding in order to finance operations.
• The company's business is highly dependent on the success of its product candidates, particularly RAP-219 for focal epilepsy.
• The regulatory approval processes of the FDA, EMA, and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable.
• The company is dependent on a third party having accurately generated, collected, interpreted and reported data from certain preclinical studies and clinical trials that were previously conducted for its product candidates.
• The company relies on third parties to assist in conducting its clinical trials.
• The company depends on in-licensed intellectual property.
• The company or its licensors may be unable to obtain and maintain patent protection for its product candidates.

Future Outlook

The company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through the end of 2026.

Management Comments

• With growing confidence in RAP-219 and a commitment to disciplined capital allocation, we are deferring further investment in RAP-199 and focusing our resources on execution of our three RAP-219 proof-of-concept clinical trials.

Industry Context

The company is operating in the competitive biopharmaceutical industry, specifically targeting central nervous system disorders, which have historically faced challenges in drug development. The company's focus on RAP technology and specific receptor targets is a differentiated approach.

Comparison to Industry Standards

• The company's cash burn rate is typical for a clinical-stage biopharmaceutical company, but the company's cash runway is longer than many of its peers.
• The company's reliance on third-party manufacturers and CROs is standard practice in the industry.
• The company's focus on a specific receptor target (TARP g 8) is a differentiated approach compared to companies developing broader-acting CNS drugs.
• The company's use of iEEG data as a primary endpoint in its Phase 2a trial is novel and may be viewed as a risk by some investors.

Management Changes

Related Party Transactions

• For the nine months ended September 30, 2024 and 2023, the Company incurred costs of $ 69 thousand and $ 0.2 million, respectively, which was recognized as research and development expense in the condensed consolidated statement of operations and comprehensive loss, to Janssen for the use of lab space in California.
• For the nine months ended September 30, 2024 and 2023, the Company incurred costs of $ 0.1 million and $ 1.0 million, respectively, of which zero and $ 0.3 million, respectively, was recognized as research and development expense, and $ 0.1 million and $ 0.7 million, respectively, was recognized as general and administrative expense in the condensed consolidated statement of operations and comprehensive loss to Third Rock primarily for management consulting and other various start-up support activities.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the company's financial performance and clinical trial updates.
• Employees may be affected by changes in the company's strategic direction and resource allocation.
• Patients may be impacted by the progress and potential delays in the development of new treatments.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will work to resolve the FDA clinical hold on the Phase 2a trial of RAP-219 for diabetic peripheral neuropathic pain.
• The company will complete the second MAD clinical trial of RAP-219 by the end of 2024.
• The company will release topline results from the second MAD clinical trial and the Phase 1 PET clinical trial in the first quarter of 2025.
• The company will continue patient recruitment and screening for the Phase 2a proof-of-concept trial in focal epilepsy.
• The company will initiate a Phase 2a trial for the treatment of bipolar disorder in 2025.

Key Dates

Keywords

RAP-219, focal epilepsy, peripheral neuropathic pain, bipolar disorder, clinical trials, FDA, biopharmaceutical, TARP g 8, AMPA receptor, CNS disorders